Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma

Tomer M. Mark; Isaac A. Bowman; Adriana C. Rossi; Manan Shah; Melissa Rodriguez; Ryann Quinn; Roger N. Pearse; Faiza Zafar; Karen Pekle; David Jayabalan; Scott Ely; Morton Coleman; Selina Chen-Kiang; Ruben Niesvizky

doi:10.3109/10428194.2014.896005

Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma

Tomer M. Mark, Isaac A. Bowman, Adriana C. Rossi, Manan Shah, Melissa Rodriguez, Ryann Quinn, Roger N. Pearse, Faiza Zafar, Karen Pekle, David Jayabalan, Scott Ely, Morton Coleman, Selina Chen-Kiang, Ruben Niesvizky

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

We studied T-BiRD (thalidomide [Thalomid^®], clarithromycin [Biaxin^®], lenalidomide [Revlimid^®] and dexamethasone) in symptomatic, newly diagnosed multiple myeloma. In 28-day cycles, patients received dexamethasone 40 mg/day on days 1, 8, 15, 22, clarithromycin 500 mg twice daily on days 1-28; lenalidomide 25 mg/day on days 1-21; and thalidomide 100 mg/day (50 mg/day on days 1-7 of cycle 1 only) on days 1-28. Twenty-six patients received a median of 6 cycles (range 0-41). Overall response rate (ORR) was 80% for the group and 100% in 11 patients who underwent autologous stem cell transplantation as part of first-line therapy. The 4-year overall survival rate was 74.9%, and the median progression-free survival was 35.6 months. Eight patients discontinued due to regimen toxicity. Grade 3 non hematologic toxicity affected 12 patients (46.2%). T-BiRD is a highly active regimen with potential toxicity limitations. ClinicalTrials.gov

Original language	English (US)
Pages (from-to)	2842-2849
Number of pages	8
Journal	Leukemia and Lymphoma
Volume	55
Issue number	12
DOIs	https://doi.org/10.3109/10428194.2014.896005
State	Published - Dec 1 2014

Keywords

Clarithromycin
Dexamethasone
Lenalidomide
Newly diagnosed multiple myeloma
Thalidomide

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.3109/10428194.2014.896005

Cite this

Mark, T. M., Bowman, I. A., Rossi, A. C., Shah, M., Rodriguez, M., Quinn, R., Pearse, R. N., Zafar, F., Pekle, K., Jayabalan, D., Ely, S., Coleman, M., Chen-Kiang, S., & Niesvizky, R. (2014). Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma. Leukemia and Lymphoma, 55(12), 2842-2849. https://doi.org/10.3109/10428194.2014.896005

Mark, TM, Bowman, IA, Rossi, AC, Shah, M, Rodriguez, M, Quinn, R, Pearse, RN, Zafar, F, Pekle, K, Jayabalan, D, Ely, S, Coleman, M, Chen-Kiang, S & Niesvizky, R 2014, 'Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma', Leukemia and Lymphoma, vol. 55, no. 12, pp. 2842-2849. https://doi.org/10.3109/10428194.2014.896005

@article{9570ba100deb446984a9f50977c7b019,

title = "Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma",

abstract = "We studied T-BiRD (thalidomide [Thalomid{\textregistered}], clarithromycin [Biaxin{\textregistered}], lenalidomide [Revlimid{\textregistered}] and dexamethasone) in symptomatic, newly diagnosed multiple myeloma. In 28-day cycles, patients received dexamethasone 40 mg/day on days 1, 8, 15, 22, clarithromycin 500 mg twice daily on days 1-28; lenalidomide 25 mg/day on days 1-21; and thalidomide 100 mg/day (50 mg/day on days 1-7 of cycle 1 only) on days 1-28. Twenty-six patients received a median of 6 cycles (range 0-41). Overall response rate (ORR) was 80% for the group and 100% in 11 patients who underwent autologous stem cell transplantation as part of first-line therapy. The 4-year overall survival rate was 74.9%, and the median progression-free survival was 35.6 months. Eight patients discontinued due to regimen toxicity. Grade 3 non hematologic toxicity affected 12 patients (46.2%). T-BiRD is a highly active regimen with potential toxicity limitations. ClinicalTrials.gov",

keywords = "Clarithromycin, Dexamethasone, Lenalidomide, Newly diagnosed multiple myeloma, Thalidomide",

author = "Mark, {Tomer M.} and Bowman, {Isaac A.} and Rossi, {Adriana C.} and Manan Shah and Melissa Rodriguez and Ryann Quinn and Pearse, {Roger N.} and Faiza Zafar and Karen Pekle and David Jayabalan and Scott Ely and Morton Coleman and Selina Chen-Kiang and Ruben Niesvizky",

note = "Publisher Copyright: {\textcopyright} 2014 Informa UK, Ltd.",

year = "2014",

month = dec,

day = "1",

doi = "10.3109/10428194.2014.896005",

language = "English (US)",

volume = "55",

pages = "2842--2849",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "12",

}

TY - JOUR

T1 - Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma

AU - Mark, Tomer M.

AU - Bowman, Isaac A.

AU - Rossi, Adriana C.

AU - Shah, Manan

AU - Rodriguez, Melissa

AU - Quinn, Ryann

AU - Pearse, Roger N.

AU - Zafar, Faiza

AU - Pekle, Karen

AU - Jayabalan, David

AU - Ely, Scott

AU - Coleman, Morton

AU - Chen-Kiang, Selina

AU - Niesvizky, Ruben

PY - 2014/12/1

Y1 - 2014/12/1

N2 - We studied T-BiRD (thalidomide [Thalomid®], clarithromycin [Biaxin®], lenalidomide [Revlimid®] and dexamethasone) in symptomatic, newly diagnosed multiple myeloma. In 28-day cycles, patients received dexamethasone 40 mg/day on days 1, 8, 15, 22, clarithromycin 500 mg twice daily on days 1-28; lenalidomide 25 mg/day on days 1-21; and thalidomide 100 mg/day (50 mg/day on days 1-7 of cycle 1 only) on days 1-28. Twenty-six patients received a median of 6 cycles (range 0-41). Overall response rate (ORR) was 80% for the group and 100% in 11 patients who underwent autologous stem cell transplantation as part of first-line therapy. The 4-year overall survival rate was 74.9%, and the median progression-free survival was 35.6 months. Eight patients discontinued due to regimen toxicity. Grade 3 non hematologic toxicity affected 12 patients (46.2%). T-BiRD is a highly active regimen with potential toxicity limitations. ClinicalTrials.gov

AB - We studied T-BiRD (thalidomide [Thalomid®], clarithromycin [Biaxin®], lenalidomide [Revlimid®] and dexamethasone) in symptomatic, newly diagnosed multiple myeloma. In 28-day cycles, patients received dexamethasone 40 mg/day on days 1, 8, 15, 22, clarithromycin 500 mg twice daily on days 1-28; lenalidomide 25 mg/day on days 1-21; and thalidomide 100 mg/day (50 mg/day on days 1-7 of cycle 1 only) on days 1-28. Twenty-six patients received a median of 6 cycles (range 0-41). Overall response rate (ORR) was 80% for the group and 100% in 11 patients who underwent autologous stem cell transplantation as part of first-line therapy. The 4-year overall survival rate was 74.9%, and the median progression-free survival was 35.6 months. Eight patients discontinued due to regimen toxicity. Grade 3 non hematologic toxicity affected 12 patients (46.2%). T-BiRD is a highly active regimen with potential toxicity limitations. ClinicalTrials.gov

KW - Clarithromycin

KW - Dexamethasone

KW - Lenalidomide

KW - Newly diagnosed multiple myeloma

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=84919421278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919421278&partnerID=8YFLogxK

U2 - 10.3109/10428194.2014.896005

DO - 10.3109/10428194.2014.896005

M3 - Article

C2 - 24576165

AN - SCOPUS:84919421278

SN - 1042-8194

VL - 55

SP - 2842

EP - 2849

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 12

ER -

Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this